Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 66, Issue 10, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/aac.00591-22
Keywords
ceftazidime-avibactam; colistin; Enterobacterales; pharmacodynamics; machine learning
Categories
Funding
- National Institute of Allergy and Infectious Diseases of the National Institutes of Health [UM1AI104681]
- National Institutes of Health [R01AI143910]
- National Institute of Allergy and Infectious Diseases [R01AI146241]
- National Institute of General Medical Sciences [T32GM086330]
- Fujian Science and Technology Innovation Joint Project [2019Y9051]
- NIH/NIAID [ARLG UM1AI104681]
- Merck
- Pfizer
- Roche
- QPex
- Utility
- Entasis
- Karius
- Union
- NIH
- AstraZeneca
- Amgen
- Gilead
- GSK
- bioMerieux
- Meiji Seika
- MSD
- Chugai
- Shionogi
- ARLG NIA
- NIA
- VA Merit Review
- Venato Rx
Ask authors/readers for more resources
This study utilized a system-based approach to analyze the impact of colistin and ceftazidime-avibactam mono- or combination therapies on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infections. The findings suggest that combination therapy may improve bacterial killing. A unified model incorporating clinical, bacterial, and drug variables can be used to evaluate clinical outcomes.
Antimicrobial resistance is a global threat. As proof-of-concept, we employed a system-based approach to identify patient, bacterial, and drug variables contributing to mortality in patients with carbapenem-resistant Klebsiella pneumoniae (CRKp) bloodstream infections exposed to colistin (COL) and ceftazidime-avibactam (CAZ/AVI) as mono- or combination therapies. Patients (n = 49) and CRKp isolates (n = 22) were part of the Consortium on Resistance Against Carbapenems in Klebsiella and other Enterobacteriaceae (CRACKLE-1), a multicenter, observational, prospective study of patients with carbapenem-resistant Enterobacterales (CRE) conducted between 2011 and 2016. Pharmacodynamic activity of mono- and combination drug concentrations was evaluated over 24 h using in vitro static time-kill assays. Bacterial growth and killing dynamics were estimated with a mechanism-based model. Random Forest was used to rank variables important for predicting 30-day mortality. Isolates exposed to COL+CAZ/AVI had enhanced early bacterial killing compared to CAZ/AVI alone and fewer incidences of regrowth compared to COL and CAZ/AVI. The mean coefficient of determination (R-2) for the observed versus predicted bacterial counts was 0.86 (range: 0.75 - 0.95). Bacterial subpopulation susceptibilities and drug mechanistic synergy were essential to describe bacterial killing and growth dynamics. The combination of clinical (hypotension), bacterial (IncR plasmid, aadA2, and sul3) and drug (KC50) variables were most predictive of 30-day mortality. This proof-of-concept study combined clinical, bacterial, and drug variables in a unified model to evaluate clinical outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available